Analyst Sees Value in Palantir, JD.com, AstraZeneca, Baidu Despite Economic Uncertainty
• Palantir Technologies has competitive advantages with its Gotham and Foundry platforms that support a premium valuation despite trading at over 50x forward earnings.
• JD.com is positioned to benefit from China's economic reopening and e-commerce growth, and its direct-to-consumer model gives it more control over margins.
• AstraZeneca's oncology and cardiovascular drug portfolios are driving growth, and the healthcare space is resistant to economic downturns. The Alexion acquisition also secures long-term rare disease cash flows.
• Baidu dominates China's search engine market with over 60% share for almost a decade, and its Apollo Go and AI Cloud businesses offer strong growth potential.
• The author sees current valuations as good entry points, with JD.com trading at a forward P/E of 8 and Baidu below 11x forward earnings.